Skip to main content

Table 1 Patient characteristics (ITT population)

From: DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study

Baseline characteristics Vandetanib 100 mg
(n= 10)
Vandetanib 300 mg
(n= 12)
Median age, years (range) 62.5 (38--77) 61 (41--73)
Male (%) 6 (60) 5 (42)
Female (%) 4 (40) 7 (58)
Race   
   Caucasian (%) 10 (100) 12 (100)
WHO performance status (%)   
0
1
6 (60)
4 (40)
8 (67)
4 (33)
Previous chemotherapy regimens (%)   
   Any 10 (100) 12 (100)
   1 1 (10) 4 (33)
   2 3 (30) 2 (17)
   3 or more 6 (60) 6 (50)
Prior cetuximab therapy (%) 7 (70) 7 (58)
Prior bevacizumab therapy (%) 5 (50) 4 (33)